Finch Therapeutics Group, Inc. (FNCH)
Company Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Country | United States |
Founded | 2017 |
IPO Date | Mar 19, 2021 |
Industry | Biotechnology |
Sector | Health Care |
Employees | 189 |
Contact Details
Address:
200 Inner Belt Road Somerville, MA 02143 United States | |
Phone | 617 229 6499 |
Website | finchtherapeutics.com |
Stock Details
Ticker Symbol | FNCH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | US Dollars |
IPO Price | $17.00 |
CIK Code | 1733257 |
ISIN Number | US31773D1019 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Mark Burnham Smith Ph.D. | Chief Executive Officer and Director |
Marc B. Blaustein C.F.A., CFA, MPP | Chief Operating Officer, Principal Financial and Accounting Officer |
Joseph D. Vittiglio Esq., J.D. | Chief Business and Legal Officer and Corporate Secretary |
Bryan Gillis M.B.A. | Chief Technology Officer |
James S. Sigler | Executive Vice President of CMC |
Sonia Timberlake | Senior Vice President of Research |
Dr. Michelle L. Rose | Chief Regulatory Officer |
Dr. Howard Franklin M.B.A., M.D. | Interim Chief Medical Officer |
Dr. Alka Batycky Ph.D. | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 16, 2022 | 8-K | Current report |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jun 15, 2022 | 4 | Statement of changes in beneficial ownership of securities |